Nouveaux hypolipémiants : prospectives = New lipid-lowering drugs: Future prospectsFARNIER, Michel.Thérapie (Paris). 2003, Vol 58, Num 1, pp 97-105, issn 0040-5957, 9 p.Article

Hypolipaemic effect of guanfacine: Two years' follow-upHAUGER-KLEVENE, J. H.Drugs under experimental and clinical research. 1984, Vol 10, Num 2, pp 133-140, issn 0378-6501Article

In vitro studies on the distribution of probucol among human plasma lipoproteinsSAIK URIEN; RIANT, P; ALBENGRES, E et al.Molecular pharmacology. 1984, Vol 26, Num 2, pp 322-327, issn 0026-895XArticle

Utilization of glucose and palmitate during adipose conversion of OB17 cells. Modulation by hypolipidemic drugsGHIS, M. P; VERRANDO, P; NEGREL, R et al.Journal de pharmacologie. 1984, Vol 15, Num 1, pp 17-25, issn 0021-793XArticle

Effect of clofibrate on brain mevalonate-5-pyrophosphate decarboxylaseZAFRA, M. F; RIQUELME, S; CASTILLO, M et al.Neurochemical research. 1987, Vol 12, Num 9, pp 787-790, issn 0364-3190Article

Plantes à saponine et régulation des dyslipémies = Saponine inplants and dyslipemiasBERGERET, C.Cahiers de biothérapie (Paris). 1984, Num 81, pp 55-57, issn 0301-1178Article

Shifting views on lipid lowering therapyKRUMHOLZ, Harlan; HAYWARD, Rodney.BMJ (Overseas and retired doctors ed.). 2010, Vol 341, Num 7768, pp 332-333, issn 1759-2151, 2 p.Article

Biological activity of the hypolipidemic agent, N²-n-butylindazoloneHALL, I. H; WILLIAMS, W. L. JR; WYRICK, S. D et al.Journal of pharmaceutical sciences. 1984, Vol 73, Num 12, pp 1788-1791, issn 0022-3549Article

Effects of procetofen on serum lipids and lipoproteins and on plasma post-heparin lipase activities in type II and in type IV hyperlipoproteinemic patientsSOMMARIVA, D; BONFIGIOLI, D; POGLIAGHI, I et al.Current therapeutic research. 1983, Vol 34, Num 5, pp 907-915, issn 0011-393XArticle

Cardiac and hepatic acyl-CoA and acylcarnitine hydrolase activities in clofibrate-fed rabbitsMOORE, K. H; SOLOMON, F. J.Comparative biochemistry and physiology. C. Comparative pharmacology. 1985, Vol 80, Num 2, pp 355-359, issn 0306-4492Article

Disposition of etofibrate, clofibric and nicotinic acid esters, and their products in dogsGARRETT, E. R; ALTMAYER, P.Journal of pharmaceutical sciences. 1985, Vol 74, Num 3, pp 295-299, issn 0022-3549Article

Hépatotoxicité des hypolipémiantsLARREY, Dominique.Hépato-gastro (Montrouge). 2004, Vol 11, Num 6, pp 407-413, issn 1253-7020, 7 p.Article

Hypolipidemic agents of phthalimide derivatives. VI: Effects of aromatic vs. non-aromatic imidesCHAPMAN, J. M. JR; WYRICK, S. D; MAGUIRE, J. H et al.Pharmaceutical research. 1984, Num 6, pp 267-269, issn 0724-8741Article

PANORAMA ACTUEL DES MEDICAMENTS HYPOLIPEMIANTSHELLER F; HARVENGT C.1980; BULL. SOC. PHARM. LILLE; ISSN 0366-3507; FRA; DA. 1980; VOL. 36; NO 3-4; PP. 209-219; BIBL. 3 P.Article

INDUCTION OF HEPATIC LONG-CHAIN ACYL-COA HYDROLASE BY CLOFIBRIC ACID ADMINISTRATIONKAWASHIMA Y; KATOH H; NAKAJIMA S et al.1983; BIOCHIMICA ET BIOPHYSICA ACTA; ISSN 0006-3002; NLD; DA. 1983; VOL. 752; NO 1; PP. 182-185; BIBL. 27 REF.Article

ESTUDIO CLINICO DEL EFECTO HIPOLIPEMIANTE DEL ACETATO DE FENOXITETRALINA (CH13437) = ETUDE CLINIQUE DES EFFETS HYPOLIPEMIANTS DE L'ACETATE DE PHENOXYTETRALINE (CH13437)1970; REV. MED. HOSP. COLONIA; MEX.; DA. 1970; VOL. 18; NO 104; PP. 133-136; BIBL. 6REF.Serial Issue

RECIPROCAL RESPONSES TO CLOFIBRATE IN KETOGENESIS AND TRIGLYCERIDE AND CHOLESTEROL SECRETION IN ISOLATED RAT LIVERIDE T; OKU H; SUGANO M et al.1982; METABOLISM, CLINICAL AND EXPERIMENTAL; ISSN 0026-0495; USA; DA. 1982; VOL. 31; NO 10; PP. 1065-1072; BIBL. 61 REF.Article

Influence du clofibrate sur la distribution subcellulaire des enzymes hépatiques du ratPANCHENKO, L. F; POPOVA, S. V; PIROZHKOV, S. V et al.Citologiâ. 1983, Vol 25, Num 11, pp 1302-1308, issn 0041-3771Article

The Ebbs and Flows in the Development of Cholesterol-Lowering Drugs: Prospects for the FutureHAJHOSSEINY, R; SABIR, I; KHAVANDI, K et al.Clinical pharmacology and therapeutics. 2014, Vol 96, Num 1, pp 64-73, issn 0009-9236, 10 p.Article

Rapid determination of clofibric acid in human plasma by high-performance liquid chromatographyPAILLET, M; DOUCET, D; MERDJEAN, H et al.Journal of chromatography. 1986, Vol 375, Num 1, pp 179-183, issn 0021-9673Article

Proceedings/Fenofibrate, a third-generation fibric acid derivative, symposium, Dallas TX, November 15, 1986BROWN, W. V.The American journal of medicine. 1987, Vol 83, Num 5, issn 0002-9343, 89 p., BConference Proceedings

Distinction entre patients bons synthétiseurs et bons absorbeurs pour optimiser le traitement hypocholestérolémiant : Thérapeutique = Distinction between good synthesizer and good absorber patients to optimize cholesterol-lowering therapyRADERMECKER, Régis P; SCHEEN, André J.Revue médicale suisse. 2006, Vol 2, Num 76, pp 1910-1915, issn 1660-9379, 6 p.Article

À la découverte de l'ézétimibe = EzetimibeWATKINS, C.La Lettre du cardiologue. 2004, Num 378, pp 44-45, issn 0761-5035, 2 p.Article

Lescol, vastin : Generic name : FluvastatinMALLARKEY, G.Current therapeutics. 1996, Vol 37, Num 4, pp 81-83, issn 0311-905XArticle

Current approaches to drug therapy for the hypercholesterolemic patientWITZTUM, J. L.Circulation (New York, N.Y.). 1989, Vol 80, Num 5, pp 1101-1114, issn 0009-7322, 14 p.Article